QD & GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / March 3, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Qudian Inc. (NYSE:QD)

Class Period: December 13, 2018 - January 15, 2020

Deadline: March 23, 2020
For more info:www.bgandg.com/qd

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) regulatory developments in China threatened to negatively impact Qudian's fiscal full year 2019 ("FY19") financial results; (2) Qudian's business was unprepared to mitigate the risks associated with these regulatory changes; (3) as a result, Qudian's loan portfolio was plagued by growing delinquency rates; (4) all of the foregoing made Qudian's repeated assertions concerning its FY19 financial guidance unrealistic; and (5) as a result of the foregoing, defendants' statements about its business and operations were materially false and misleading at all relevant times.

Geron Corporation(NASDAQ:GERN)

Class Period: March 19, 2018 - September 26, 2018

Deadline: March 23, 2020
For more info:www.bgandg.com/gern

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) misled investors about the results of a clinical drug study of imetelstat called IMbark; and (2) as a result, defendants' statements about Geron's business, operations, and prospects were materially false and misleading and lacked a reasonable basis at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC